Gajewski TF. The next hurdle in cancer immunotherap y: overcoming the non-T- cell- inflamed tumor microenvironment. Semin Oncol. 2015; 42:663–71. 49. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015; 348:56 –61. 50. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti- PD-L1 antibod y MPDL 3280A in cancer patients. Nature.